Company Announcement - AB Science SA has postponed the publication of its 2024 annual financial report from April 30, 2025, to May 9, 2025, to allow auditors to complete their work [1][2] Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3] - The company's lead compound, masitinib, is registered for veterinary medicine and is being developed for human medicine in areas such as oncology, neurological diseases, inflammatory diseases, and viral diseases [4] Additional Information - AB Science is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [4] - Further information can be found on the company's website [5]

AllianceBernstein (AB) Q1 2025 Earnings Call April 24, 2025 09:00 PM ET Company Participants Ioanis Jorgali - Vice President of Investor RelationsSeth Bernstein - President and CEOTom Simeone - CFOAlexander Blostein - Managing DirectorOnur Erzan - Head of Global Client Group & Head of Bernstein Private WealthCraig Siegenthaler - Managing DirectorBenjamin Budish - Director Conference Call Participants William Katz - Senior Equity AnalystDaniel Fannon - Managing Director - Research AnalystJohn Dunn - Analyst ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-09818 For the quarterly period ended March 31, 2025 ALLIANCEBERNSTEIN HOLDING L.P. (Exact name of registrant as specified in its charter) Delaware 13-3434400 (State or other jurisd ...

Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES FIRST QUARTER RESULTS GAAP Net Income of $0.67 per Unit Adjusted Net Income of $0.80 per Unit Cash Distribution of $0.80 per Unit Nashville, TN, April 24, 2025 - AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today reported financial and operating results for the quarter ended ...

GAAP Net Income of $0.67 per Unit Adjusted Net Income of $0.80 per Unit Cash Distribution of $0.80 per Unit NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today reported financial and operating results for the quarter ended March 31, 2025. "Against a tough market backdrop that intensified into the second quarter, all three of our global distribution channels grew organically, totaling $2.7 billion active net inflows ...

Core Viewpoint - The European Medicines Agency (EMA) has granted orphan drug designation to AB8939 for the treatment of acute myeloid leukemia (AML), indicating its potential significant benefit over existing therapies [1][2]. Group 1: Orphan Drug Designation - AB8939 previously received orphan drug designation from the US FDA, and the EU designation is a significant milestone, suggesting that it offers substantial benefits to AML patients [2]. - The criteria for orphan drug designation at EMA are stringent, requiring evidence of significant benefit compared to existing treatments [2][4]. Group 2: Efficacy and Safety Data - Preclinical data from mouse models show that AB8939 provides a significant benefit over current therapies like cytarabine, azacitidine, and venetoclax [3]. - Preliminary efficacy and safety data from Phase 1 trials indicate that AB8939 is effective as a monotherapy with different treatment cycles [3]. - AB8939 demonstrates efficacy against drug-resistant AML cells, with 45% of vincristine-resistant and 66% of cytarabine-resistant cells responding to treatment [4]. Group 3: Mechanism of Action - AB8939 is a synthetic molecule that targets cancer cells by destabilizing microtubules essential for cell division and inhibiting enzymes crucial for cancer stem cell survival [6]. - The chemical name of AB8939 is '1-{4-[2-(5-ethoxymethyl-2-methylphenylamino)-oxazol-5-yl]phenyl}imidazolidin-2-one' [6]. Group 4: Benefits of Orphan Drug Designation - Orphan drug designation in the EU provides various benefits, including scientific advice on product development, access to centralized marketing authorization, and potential financial incentives [8]. - If approved, AB8939 will enjoy 10 years of marketing exclusivity from the date of registration, provided the orphan designation remains valid [8].

I rate AllianceBernstein Holding L.P. (NYSE: AB ) as a Buy, for capital appreciation focused investors who are looking for long-term buy and hold investments. AB will declare Q1 earnings on April 24 th and is widely expectedDavid A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As an investor entrepreneur, David invests in stocks, bonds, options, ETFs, REITs, real estate, closed end funds and alternative investment funds such as hedge funds and pri ...

Core Viewpoint - AB Science has received a Notice of Allowance for a US patent covering the use of masitinib in treating sickle cell disease, providing protection until November 2040, which enhances its intellectual property portfolio [1][3]. Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [12][13]. Product Development - Masitinib is being developed as a treatment for severe forms of sickle cell disease, which accounts for approximately 65% of cases. The drug targets mast cells, which play a critical role in the disease's complications [3][4]. - The clinical development of masitinib in sickle cell disease is part of the SICKMAST collaborative program, which is funded with €9.2 million and aims to demonstrate efficacy in a phase 2 clinical trial [5]. Medical Need - Sickle cell disease is a significant public health challenge, with around 300,000 children born with the condition annually, potentially rising to 400,000 by 2050. The disease leads to early death and high social burden [6][10]. - Current treatment options do not fully prevent life-threatening complications, highlighting a significant medical need for effective therapies [10]. Scientific Insights - Masitinib has shown survival benefits in preclinical models, with treated mice experiencing no vaso-occlusive crises (VOC) or deaths, indicating its potential effectiveness [4]. - The drug acts as an inhibitor of key kinases involved in mast cell activation, which is crucial for addressing the inflammatory aspects of sickle cell disease [8][9].

NASHVILLE, Tenn., April 9, 2025 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management decreased to $784 billion during March 2025 from $805 billion at the end of February. Net inflows across all three channels (Institutional, Retail and Private Wealth) were offset by market depreciation during March, resulting in a 2.6% decline in month-end AUM. For the quarter-ended March 2025, preliminary firmwide ...

NASHVILLE, Tenn., April 7, 2025 /PRNewswire/ -- AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that First Quarter 2025 financial and operating results will be released before the market opens on Thursday, April 24, 2025. Management will conduct a teleconference beginning at 9:00 am (CT), to discuss the results. The call will be hosted by Seth Bernstein, President and Chief Executive Officer; Thomas Simeone, Chief Financial Officer; and Onur Erzan, Head of Global Client ...